Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

Tilo had been born with a genetic disorder that had impeded his growth, resigning him to dwarfism. This condition is the ...

Layla-Grace is a happy, determined and chatty little girl who loves music and playing outside. The 18-month-old has been ...

Surgeons at the Department of Neurosurgery, J.N. Medical College, Aligarh Muslim University have performed a rare surgery to ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

5 6 We report the case of a child, born to unaffected parents, with phenotypic features of both achondroplasia and NPS. De novo heterozygous mutations were identified in both theFGFR3 and LMX1Bgenes, ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...